about
Elongation factor-2 phosphorylation in dendrites and the regulation of dendritic mRNA translation in neuronsImportance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapsesThe postsynaptic density proteins Homer and Shank form a polymeric network structurePharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice.Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous systemPhosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2Synaptic activity controls dendritic spine morphology by modulating eEF2-dependent BDNF synthesisRegulated RalBP1 binding to RalA and PSD-95 controls AMPA receptor endocytosis and LTDProteomic analysis of activity-dependent synaptic plasticity in hippocampal neurons.Anti-angiogenic therapy induces integrin-linked kinase 1 up-regulation in a mouse model of glioblastomaCombination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.Antiangiogenic therapy for glioma.Comparative neuronal differentiation of self-renewing neural progenitor cell lines obtained from human induced pluripotent stem cells.Glial degeneration with oxidative damage drives neuronal demise in MPSII disease.Proteomic Analysis of Post-synaptic Density Fractions from Shank3 Mutant Mice Reveals Brain Region Specific Changes Relevant to Autism Spectrum Disorder.Molecular and synaptic defects in intellectual disability syndromes.Scaffold proteins at the postsynaptic density.Molecular basis for prospective pharmacological treatment strategies in intellectual disability syndromes.Mutations of the synapse genes and intellectual disability syndromes.Shank synaptic scaffold proteins: keys to understanding the pathogenesis of autism and other synaptic disorders.The X-Linked Intellectual Disability Protein IL1RAPL1 Regulates Dendrite Complexity.Modelling Autistic Neurons with Induced Pluripotent Stem Cells.The GluR2 subunit inhibits proliferation by inactivating Src-MAPK signalling and induces apoptosis by means of caspase 3/6-dependent activation in glioma cells.Dimerizable redox-sensitive triazine-based cationic lipids for in vitro gene delivery.Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target.SHANK3 gene mutations associated with autism facilitate ligand binding to the Shank3 ankyrin repeat region.Functional and molecular defects of hiPSC-derived neurons from patients with ATM deficiencySynaptic localization and activity of ADAM10 regulate excitatory synapses through N-cadherin cleavage.eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures.Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.Expression of cocaine-evoked synaptic plasticity by GluN3A-containing NMDA receptors.The neuropeptide PACAP38 induces dendritic spine remodeling through ADAM10-N-cadherin signaling pathway.CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons.Homer1b/c clustering is impaired in Phelan-McDermid Syndrome iPSCs derived neuronsSpikar speaks to spines and nucleiSOD1 stimulates lamellipodial protrusions in Neuro 2A cell linesAutism-associated SHANK3 mutations impair maturation of neuromuscular junctions and striated muscles
P50
Q21129477-5F31186D-D4DE-4638-8A13-B7D17139EFB5Q24317227-F9D2ECB0-BC94-43FC-AEE4-1373F93CE453Q24645689-7770DB9B-9E7C-4D49-B42C-F78DD400C14EQ27318675-B577CBA1-E157-4440-8A0A-ACBA5934D28BQ27659896-CFECE8F9-1CF5-4F0D-901C-A19E33333C07Q27687074-43577378-F3CD-4F91-9E8A-C9594F4C3BEEQ28577398-C1F85AFA-9121-4F91-B16F-4D86651F615FQ28582590-B58848F6-0153-4D21-9DD0-2A53735DB307Q33290417-7081DB27-35A5-44BD-9BA3-145982BDFD9BQ33741854-99458B08-3446-4743-ACF5-B2CB87CDE4C6Q34253705-D5AAC27C-1C8A-43EA-A8E7-7C8D9A662033Q36101999-5609BBDB-C5F6-440B-B14E-1B76C35A0A71Q37217420-833B91BA-77E4-405D-8D27-370952750839Q37412488-831BE687-F0F9-46A9-95F3-AC4926EFBF32Q37639891-5AA69A3F-2077-4B81-A124-6AC958016C3DQ37946011-A39DDAF2-93C9-4229-9243-326854D92257Q37986647-B493A350-238F-4A7E-A477-F30928712332Q38108556-7275B01D-1879-4930-852D-FC5DC804F64EQ38122977-B288EC66-0A8D-43D4-8D0E-364D04D87C56Q38580572-B2B673B5-BDC7-4385-A0B6-D93272C6D58AQ38747493-7F3287E5-A1EE-4BA5-B394-6DDDD2A0A769Q39334479-F515288A-DB8C-42F4-95F4-DE1410CD5071Q39832584-6AFF8BAD-69F4-46F5-8E9A-46AA39F6D088Q40189995-942AF2F9-211A-444F-BC7A-441B1D603A5DQ41159026-FF32C3A3-9CEB-409F-B4AE-EE9ACA5B42CFQ42611129-F287FD4F-6437-4378-8629-002DA08C89DAQ42771888-78BAB211-8E07-4652-A1A1-35768288096AQ42788398-0E5D47A1-C0C2-4D07-A37F-C222C0CCAF0DQ47448046-2A0B99D6-8DCE-4907-A7CD-2FD0D66541CCQ47831155-753A20DF-DDDB-4FDC-892F-963B77BDAF16Q47954515-862712C5-FEA0-4893-8FC5-419F0531B7B1Q48663297-B34C0459-3CBC-417F-B66F-B42DEAD6ECDCQ50305506-2833A5B5-15C2-449E-8B58-4EEAEA306ECCQ58065883-BE26D458-D1D3-4762-8593-3F09FB29FF7DQ58065947-7D7C79B9-05E1-4CB4-88D1-47275F19E940Q58792227-63DEBFAC-9D9B-4D43-8E46-B5433E1839E4Q96302666-2F988E0E-7D88-40AD-A901-0227D6F81DF4
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chiara Verpelli
@ast
Chiara Verpelli
@en
Chiara Verpelli
@es
Chiara Verpelli
@nl
Chiara Verpelli
@sl
type
label
Chiara Verpelli
@ast
Chiara Verpelli
@en
Chiara Verpelli
@es
Chiara Verpelli
@nl
Chiara Verpelli
@sl
prefLabel
Chiara Verpelli
@ast
Chiara Verpelli
@en
Chiara Verpelli
@es
Chiara Verpelli
@nl
Chiara Verpelli
@sl
P1053
K-6673-2016
P106
P21
P31
P3829
P496
0000-0003-2949-9725